Castle Biosciences (CSTL) Short-term Investments (2022 - 2026)

Castle Biosciences has disclosed Short-term Investments across 5 years of filings, most recently posting $197.9 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $197.9 million, up 6.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $197.9 million (up 6.7% YoY), and the FY2025 annual result was $182.8 million, up 5.39% from the prior year.
• Short-term Investments came in at $197.9 million for Q1 2026 at Castle Biosciences, up from $182.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $202.0 million in Q3 2025 to a low of $117.2 million in Q1 2023.
• The 5-year median for Short-term Investments is $173.4 million (2024), against an average of $163.2 million.
• Across the five-year window, Short-term Investments rose 5.08% in 2023 and soared 34.35% in 2024, its largest moves.
• Castle Biosciences' Short-term Investments stood at $135.7 million in 2022, then climbed by 6.32% to $144.3 million in 2023, then gained by 20.22% to $173.4 million in 2024, then rose by 5.39% to $182.8 million in 2025, then advanced by 8.29% to $197.9 million in 2026.
• The last three Short-term Investments figures came in at $197.9 million (Q1 2026), $182.8 million (Q4 2025), and $202.0 million (Q3 2025), per Business Quant data.